SavedAdd your journal

Journals / Düzce Tıp Fakültesi Dergisi / 2026 / Volume: 28 Issue: 2

Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report

Merve Şimşek Dilli(University of Health Sciences, Adana Health Practice and Research Center, Department of Endocrinology)0009-0000-0493-946X
Fettah Acıbucu(University of Health Sciences, Adana Health Practice and Research Center, Department of Endocrinology)0000-0002-2252-2112
Zübeyde Şebnem Aktaran(University of Health Sciences, Adana Health Practice and Research Center, Department of Endocrinology)0000-0002-6978-5155
Şekure Demet Küçük(University of Health Sciences, Adana Health Practice and Research Center, Department of Endocrinology)0000-0003-3175-1256
Pages
—
Publication Date
2026-08-21
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case highlights the importance of recognizing silent corticotroph pituitary neuroendocrine tumors, the treatment approach, and long-term follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Silent corticotroph pituitary neuroendocrine tumors are a rare subtype of non-functioning pituitary neuroendocrine tumors that lack the clinical and biochemical manifestations of Cushing disease.
📊
Key Findings & Data:These tumors are associated with an aggressive clinical course because of a tendency for rapid progression and invasive growth, as well as a high recurrence rate.
💡
Conclusion & Impact:This case highlights the importance of recognizing silent corticotroph pituitary neuroendocrine tumors, the treatment approach, and long-term follow-up.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:Pituitary neoplasms · cushing disease · adrenocorticotropic hormone

Abstract

Silent corticotroph pituitary neuroendocrine tumors are a rare subtype of non-functioning pituitary neuroendocrine tumors that lack the clinical and biochemical manifestations of Cushing disease. These tumors are associated with an aggressive clinical course because of a tendency for rapid progression and invasive growth, as well as a high recurrence rate. We present a 41-year-old woman without Cushingoid symptoms who presented with headache, bitemporal hemianopia, and diplopia. MRI revealed a mass extending into the suprasellar region, measuring approximately 2 × 4 cm, with internal necrotic areas and post-contrast enhancement. Following transsphenoidal resection, immunohistochemical staining demonstrated positivity for adrenocorticotropic hormone, confirming the diagnosis of a silent corticotroph pituitary neuroendocrine tumor. This case highlights the importance of recognizing silent corticotroph pituitary neuroendocrine tumors, the treatment approach, and long-term follow-up.

🔖

Cite This Article

Dilli, M. Ş., Acıbucu, F., Aktaran, Z. Ş., Küçük, Ş. D. (2026). Silent Corticotroph Pituitary Neuroendocrine Tumor: A Case Report. Düzce Tıp Fakültesi Dergisi, Volume: 28 Issue: 2. https://doi.org/10.18678/dtfd.1899708

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Ioachimescu AG, Eiland L, Chhabra VS, Mastrogianakis GM, Schniederjan MJ, Brat D, et al. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery. 2012;71(2):296-303; discussion 304. doi:10.1227/NEU.0b013e318257c1f0.
  2. Cooper O. Silent corticotroph adenomas. Pituitary. 2015;18(2):225-31. doi:10.1007/s11102-014-0624-3.
  3. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol. 2022;33(1):6-26. doi:10.1007/s12022-022-09703-7.
  4. Sumislawski P, Huckhagel T, Krajewski KL, Aberle J, Saeger W, Flitsch J, et al. Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study. Sci Rep. 2023;13(1):2468. doi:10.1038/s41598-023-29628-3.
  5. Jiang S, Zhu J, Feng M, Yao Y, Deng K, Xing B, et al. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system. Pituitary. 2021;24(4):564-73. doi:10.1007/s11102-021-01133-8.
  6. Goyal-Honavar A, Sarkar S, Asha HS, Kapoor N, Balakrishnan R, Vanjare H, et al. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors. Acta Neurochir (Wien). 2021;163(11):3143-54. doi:10.1007/s00701-021-04911-2.
  7. Himstead AS, Wells AC, Kurtz JS, Moldenhauer MR, Davies JL, Fote GM, et al. Silent corticotroph adenomas demonstrate predilection for sphenoid sinus, cavernous sinus, and clival invasion compared with other subtypes. World Neurosurg. 2024;191:e41-7. doi:10.1016/j.wneu.2024.08.027.
  8. Jiang S, Chen X, Wu Y, Wang R, Bao X. An update on silent corticotroph adenomas: diagnosis, mechanisms, clinical features, and management. Cancers (Basel). 2021;13(23):6134. doi:10.3390/cancers13236134.
  9. Vitale G, Tortora F, Baldelli R, Cocchiara F, Paragliola RM, Sbardella E, et al. Pituitary magnetic resonance imaging in Cushing's disease. Endocrine. 2017;55(3):691-6. doi:10.1007/s12020-016-1038-y.
  10. Righi A, Faustini-Fustini M, Morandi L, Monti V, Asioli S, Mazzatenta D, et al. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocrine. 2017;56(2):286-97. doi:10.1007/s12020-016-1028-0.
  11. Langlois F, Lim DST, Yedinak CG, Cetas I, McCartney S, Cetas J, et al. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary. 2018;21(1):32-40. doi:10.1007/s11102-017-0844-4.
  12. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521-35. doi:10.1007/s00401-017-1769-8.
  13. Yamamoto M, Nakao T, Ogawa W, Fukuoka H. Aggressive Cushing's disease: molecular pathology and its therapeutic approach. Front Endocrinol (Lausanne). 2021;12:650791. doi:10.3389/fendo.2021.650791.
  14. Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol. 2015;26(4):349-55. doi:10.1007/s12022-015-9398-z.
  15. Demarchi G, Perrone S, Esper Romero G, De Bonis C, Casasco JP, Sevlever G, et al. Case report: progression of a silent corticotroph tumor to an aggressive secreting corticotroph tumor, treated by temozolomide. Changes in the clinic, the pathology, and the β-catenin and α-SMA expression. Front Endocrinol (Lausanne). 2022;13:870172. doi:10.3389/fendo.2022.870172.
  16. Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17(11):671-84. doi:10.1038/s41574-021-00550-w.
  17. Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, et al. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery. 2013;73(1):8-17; discussion 17-8. doi:10.1227/01.neu.0000429858.96652.1e.